Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Pomalidomide, cyclophosphamide and dexamethasone (PCd) shows ORR of 59.8% in RRMM (52.3% in triple-refractory pts); median PFS & OS were 7.9 & 16.1 months; pts refractory to len & anti-CD38 had a median PFS of 7.6 months.”
Title: Pomalidomide, Cyclophosphamide and Dexamethasone (PCd): Outcomes in Patients With Double- or Triple-Refractory Multiple Myeloma
Authors: Marta Hidalgo-Soto, Luis Rodríguez-Lobato, Cristina Motlló Borrella, Ángela Sánchez Cayuela, Jordi Lopez Pardo, Laura Rosiñol, Maria-Teresa Cibeira, Antoni García-Guiñon, Carles Tolosa-Ridao, Itziar Carro Arostegui, Anna Sureda, María José Herranz, Eugenia Abella, Meritxell Pelicano, Yaiza Barrau Alzuria, Montserrat Cortes Sansa, Mercedes Gironella, Yolanda González, Carlos Fernández De Larrea
You can read the Full Article in European Journal of Haematology.
You can find more posts featuring Robert Orlowski on OncoDaily.
